Clinical trials: Body Weight Control
Muscle Loss, Obesity
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.
- Trial name
- QUALITY (NCT06282458)
- Testing
- Enobosarm, Semaglutide
- Where
- 14 sites in United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Veru Inc.
Obesity, Overweight
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with obesity or overweight. Participation in the study will last about one year.
- Trial name
- NCT06683508
- Testing
- LY3549492
- Where
- 49 sites in United States
- Volunteers
- 288 people
- Sponsor
- Eli Lilly and Company
Healthy Volunteers, Obesity
Phase 1 Clinical Study of MWN117 Injection in Healthy Participants and Participants With Obesity
This study is a randomized, double-blind, placebo-controlled, single-dose, dose-escalation Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MWN117 injection in healthy and…
- Trial name
- NCT07824804
- Testing
- MWN117
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity
A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses
1. Study Objective i) To evaluate the safety, tolerability and pharmacokinetic/pharmacodynamic characteristics of HSG4112 after single and multiple oral administration of high doses in healthy subjects.
- Trial name
- NCT05310032
- Testing
- HSG4112
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Glaceum
Nonalcoholic Fatty Liver, Weight Loss
Study on GS300 on NAFLD
To determine the efficacy of GS300 when administered for 24 weeks in patients with Nonalcoholic Fatty Liver Disease (NAFLD).
- Trial name
- REVERT (NCT04887766)
- Testing
- GS300
- Volunteers
- 250 people
- Sponsor
- Gelesis, Inc.
Overweight, Obesity
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study
The purpose of this study is to determine whether the combination of two dietary supplements: MUSCLE 5, which contains protein, creatine and vitamin D and TRIM 7, which contains beet extract, caffeine, coenzyme Q10, alpha lipoic…
- Trial name
- NCT05384431
- Testing
- Muscle5 and TRIM7, Mixed exercise
- Where
- Canada
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Exerkine Corporation
Cachexia-Anorexia Syndrome, Cachexia; Cancer
A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia
This is a multicenter, randomized, double-blind, placebo-controlled, dose-finding Phase II clinical study to evaluate the efficacy and safety of SXRN injection in adult patients with cancer-associated anorexia-cachexia.
- Trial name
- NCT07890324
- Testing
- SXRN Injection
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Jiangsu Guiqiong Pharmaceutical Co., Ltd.
Heart Failure
A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants
Vericiguat (BAY1021189) is under development to treat heart failure, a condition in in which the heart has trouble pumping blood through the body.
- Trial name
- NCT04722562
- Testing
- Vericiguat (BAY1021189)
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bayer
Overweight or Obese Participants Without Diabetes
A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes
To evaluate the efficacy of BGM0504 tablets compared with placebo in reducing body weight in overweight or obese participants without diabetes after 20 weeks of treatment.
- Trial name
- NCT07658560
- Testing
- BGM0504 tablets
- Where
- China
- Volunteers
- 200 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Obesity, Overweight
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
Overweight and obesity are long-term health conditions that can increase the risk of serious health problems, including heart disease, type 2 diabetes, and other medical conditions.
- Trial name
- NCT07792954
- Testing
- Berobenatide
- Where
- 34 sites in China
- Volunteers
- 300 people
- Sponsor
- Pfizer
Obesity, Overweight
Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects
The purpose of this Phase 3b study is to assess the effects of combination therapy with naltrexone SR/bupropion SR (NB) used in conjunction with a comprehensive lifestyle intervention (CLI) and in a manner consistent with its…
- Trial name
- NCT01764386
- Testing
- NB, CLI, Usual Care
- Where
- 15 sites in United States
- Volunteers
- 242 people
- Sponsor
- Orexigen Therapeutics, Inc
Obesity
An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Patients (0364-037)(TERMINATED)
A 1 year worldwide study in obese and overweight patients to assess the safety and effect on body weight of an investigational weight loss drug.
- Trial name
- NCT00384605
- Testing
- taranabant
- Volunteers
- 1,000 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity, Overweight
A Research Study of VCT220 in Adult Chinese Participants With Obesity
The main purpose of this study is to assess how VCT220 tablets affect the bodyweight in obese or overweight adult participants. Participant will be randomly assigned to the high-dose group, low-dose group, or placebo group.
- Trial name
- NCT06939296
- Testing
- VCT220
- Where
- China
- Volunteers
- 840 people
- Sponsor
- Vincentage Pharma Co., Ltd
Obesity/Overweight
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study in adult obese/overweight subjects in China to evaluate the efficacy and safety of GZR18 Injection in the subjects.
- Trial name
- NCT06728124
- Testing
- GZR18
- Where
- China
- Volunteers
- 630 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Obesity and Cardiovascular Risk
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation.
- Trial name
- QUELL-CV (NCT07656727)
- Testing
- Oral BGE-102
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 160 people
- Sponsor
- BioAge Labs, Inc.
Diabetes Mellitus, Type 2, Obesity
Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus
This trial will evaluate use of BI 10773 as add-on to insulin regimen alone or with metformin in patients with typr 2 diabetes. Both lowering glucose and HbA1c and reducing the use of insulin in this population would provide…
- Trial name
- NCT01306214
- Testing
- BI 10773
- Where
- 103 sites in United States, Belgium and 12 more
- Volunteers
- 566 people
- Sponsor
- Boehringer Ingelheim
Obesity
A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity
This study tests if semaglutide tablets of 50 mg can help people with obesity to lower their food intake compared to placebo. This study also tests how semaglutide 50 mg works on appetite, control of eating (such as cravings and…
- Trial name
- NCT05236517
- Testing
- Semaglutide D Dose 1, Semaglutide D Dose 2, Semaglutide D Dose 3
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Muscle Function, Mitochondrial Function, Overweight
AMAZ-02 Effect on Exercise ToLerance in Healthy, Overweight Middle Aged Subjects (ATLAS Trial)
This is a Phase 2 randomized, double-blind, placebo-controlled study enrolling 90 healthy, overweight, middle aged subjects (30 placebo, 30 low dose and 30 high dose AMAZ-02 intervention), 40-65 years of age, who are otherwise…
- Conditions
- Muscle Function, Mitochondrial Function, Overweight, Healthy Aging
- Trial name
- ATLAS (NCT03464500)
- Testing
- Mitopure 500mg, Mitopure 1000mg
- Where
- Canada
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Amazentis SA
Overweight, Obesity
PH iWell Study to Compare an Online Interactive Technology to Self-directed Care in Overweight or Obese Individuals
This is a six month lifestyle management study to compare the effects of iWell; a dynamic online interactive technology to a self-directed program in overweight or obese individuals.
- Trial name
- NCT01325376
- Testing
- Technology assisted health behavior, Self directed
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- SK Telecom Americas, Inc.
Non-diabetic Overweight or Obese
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects
This is a Phase 1, single-center, randomized, placebo-controlled, ascending dose study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM0504 following…
- Trial name
- NCT07166081
- Testing
- BGM0504
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.